ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Chickenpox Vaccine

Also written as “Varicella Vaccine”, “Investigational live attenuated varicella vaccine” and “Zoster Vaccine, Live”.

Its studies are mostly in Chickenpox · Herpes Zoster · Meningococcal Infections · Measles · Streptococcal Infections, led by 6 companies.

Drug pageChickenpox Vaccine: every studyMany companies study it; this page follows only the 43 they lead. All 76 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 7, 200743 company-led studies, 6 open or runningNext primary completion: Dec 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only210 open or runningphase 4since Feb 7, 2007Apr 22, 2005none ahead
Sinovac Biotechits history only124 open or runningphase 4since Oct 14, 2021Nov 14, 2016Dec 2028phase 4 · NCT06484686
GlaxoSmithKlineits history only60 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
Sinopharm22 open or runningphase 3since Dec 20, 2022Dec 20, 2022none ahead
Changchun Changsheng Life Science and Technologyits history only10 open or runningphase 4since Oct 24, 2013Oct 24, 2013none ahead
GC Biopharmaits history only10 open or runningphase 3since Nov 28, 2017Nov 28, 2017none ahead

Also a collaborator on its studies: Beijing Institute of Biological Products.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2022First study: phase 3 study in ChickenpoxFirst studyNCT05669625 · 12,440 enrolled · China
  2. Apr 20, 2023Phase 3 study in ChickenpoxNCT05839301 · 1,200 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 2 Sinopharm leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05839301Chickenpox · China3Active, not recruitingJul 30, 20231,200
NCT05669625Chickenpox · China3Active, not recruitingApr 14, 202412,440

How it is read

Names in the registry

  • “Varicella Vaccine”, 4 entries
  • “Investigational live attenuated varicella vaccine”, 4 entries
  • “Zoster Vaccine, Live”, 3 entries
  • “Varicella Virus Vaccine Live”, 2 entries
  • “Live Attenuated Varicella Vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.